Methyl salicylate

Identification

Name
Methyl salicylate
Accession Number
DB09543
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Methyl salicylate (oil of wintergreen or wintergreen oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It is also synthetically produced, used as a fragrance, in foods and beverages, and in liniments. It forms a colorless to yellow or reddish liquid and exhibits a characteristic odor and taste of wintergreen. For acute joint and muscular pain, methyl salicylate is used as a rubefacient and analgesic in deep heating liniments. It is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions.

Structure
Thumb
Synonyms
  • 2-(Methoxycarbonyl)phenol
  • 2-Carbomethoxyphenol
  • 2-Hydroxybenzoic acid methyl ester
  • Betula oil
  • Gaultheria oil
  • Methyl 2-hydroxybenzoate
  • Methyl o-hydroxybenzoate
  • Natural wintergreen oil
  • Oil of wintergreen
  • Spicewood Oil
  • Sweet birch oil
  • Teaberry oil
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SportgelEmulsion10 %TopicalMeyer Zall Laboratories Pty Ltd.Not applicableNot applicableCanada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aspi-Rub Pain RelieverSpray23 g/100gTopicalAspi Rub Enterprises Llc2014-08-29Not applicableUs
Balsamo de Ubre MascuraOintment10.5 g/90gTopicalMenper Distributors2011-05-10Not applicableUs
Bumooly-SSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-09-25Not applicableUs
Bumooly-SSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-05-16Not applicableUs
Coats Aloe AnalgesicLotion10 g/gTopicalTychasis Corporation2015-09-29Not applicableUs
Coats Aloe AnalgesicLotion10 g/100mLTopicalTychasis Corporation2015-11-02Not applicableUs
Foot Works Arthritis Achy Foot and MuscleCream250 mg/mLTopicalNew Avon Llc2012-05-30Not applicableUs
Humco Wintergreen OilLiquid980 mg/mLTopicalHumco Holding Group. Inc.1998-03-252021-10-31Us
Hyundai Moolpas FSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-05-16Not applicableUs
Hyundai Moolpas FSolution3 g/100mLTransdermalScott Holdings Co., Ltd.2014-09-25Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Natralia Cramp ReliefGel105 mg/gTopicalLaderma Trading Pty Ltd.2009-03-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
701 Dieda Zhengtong Yaogao Medicated PlasterMethyl salicylate (10 g/1) + Camphor (3.1 g/1) + Menthol (8 g/1)PlasterTopical; TransdermalGUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO., LTD. BAIYUNSHAN HEJIGONG PHARMACEUTICAL FACTORY2001-10-15Not applicableUs
AdazinMethyl salicylate (1 g/100g) + Benzocaine (2 g/100g) + Capsaicin (.035 g/100g) + Lidocaine (2 g/100g)CreamTopicalSterling Knight Pharmaceuticals, Llc2014-12-03Not applicableUs
Advanced AntisepticMethyl salicylate (.06 mL/100L) + Eucalyptol (.042 mL/100L) + Menthol (.042 mL/100L) + Thymol (.064 mL/100L)MouthwashOralWakfern Food Corporation2010-11-24Not applicableUs
Advanced AntisepticMethyl salicylate (.06 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Thymol (.064 kg/100L)MouthwashOralDemoulas Supermarkets, Inc.2010-07-22Not applicableUs
Advanced Antiseptic CitrusMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.042 mL/100L)MouthwashOralH.E.B.2010-10-15Not applicableUs
Advanced Antiseptic CitrusMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.042 mL/100L)MouthwashOralDrug Mart1991-06-15Not applicableUs
Advanced CitrusMethyl salicylate (.06 kg/100L) + Eucalyptol (.092 kg/100L) + Menthol (.042 kg/100L) + Thymol (.064 kg/100L)MouthwashOralWalmart Stores2010-07-22Not applicableUs
Advanced Citrus AntisepticMethyl salicylate (.06 mL/100L) + Eucalyptol (.092 mL/100L) + Menthol (.042 mL/100L) + Thymol (.064 mL/100L)MouthwashOralPublix Supermarkets, Inc.2001-05-03Not applicableUs
Ageless Pain ReliefMethyl salicylate (14 mL/100mL) + Menthol (7 mL/100mL)CreamTopicalIsagenix International, Llc2011-04-23Not applicableUs
Air Sinsin PasMethyl salicylate (.361 g/100mL) + Camphor (.361 g/100mL) + Menthol (.289 g/100mL)Aerosol, sprayCutaneous; Topical; TransdermalSinsin Pharmaceutical Co., Ltd.2011-07-01Not applicableUs
Categories
UNII
LAV5U5022Y
CAS number
119-36-8
Weight
Average: 152.1473
Monoisotopic: 152.047344122
Chemical Formula
C8H8O3
InChI Key
OSWPMRLSEDHDFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3
IUPAC Name
methyl 2-hydroxybenzoate
SMILES
COC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Ointments or liniments containing methyl salicylate are applied topically as counter irritant for relief of acute pain associated with lumbago,sciatica and rheumatic conditions. Local analgesics for human and veterinary medicine.

Structured Indications
Pharmacodynamics

Methyl salicylate relieve musculoskeletal pain in the muscles, joints, and tendons by causing irritation and reddening of the skin due to dilated capillaries and increased blood flow. It is pharmacologically similar to aspirin and other NSAIDs but as a topical agent it primarily acts as a rubefacient and skin irritant. Counter-irritation is believed to cause a soothing sensation of warmth.

Mechanism of action

Counter-irritation is thought to be effective at alleviating musculoskeletal pain as the irritation of the sensory nerve endings is thought to alter or offset pain in the underlying muscle or joints that are served by the same nerves [5]. This is thought to mask the underlying musculoskeletal pain and discomfort. When applied topically, methyl salicylate is thought to penetrate the skin and underlying tissues where it reversibly inhibits cyclooxygenase enzyme and locally and peripherally prevents the production of inflammatory mediators such as prostaglandin and thromboxane A2.

Absorption

Approximately 12-20% of topically applied methyl salicylate may be systemically absorbed through intact skin within 10 hours of application, and absorption varies with different conditions such as surface area and pH. Dermal bioavailability is in the range of 11.8 – 30.7%. For the assessment of potential oral exposure to salicylates, bioavailability is assumed to be 100% [9].

Volume of distribution

After absorption, methyl salicylate is distributed throughout most body tissues and most transcellular fluids, primarily by pH dependent passive processes. Salicylate is actively transported by a low-capacity, saturable system out of the CSF across the choroid plexus. The drug readily crosses the placental barrier.

Protein binding

Degree of albumin binding depends on the plasma concentration of the compound

Metabolism

Minor metabolism may occur in various tissues but hepatic metabolism constitutes the majority of metabolic processes of absorbed methyl salicylate. It is mainly hydrolyzed to salicylic acid via hepatic esterase enzymes. Conjugation with glycine forms salicyluric acid and conjugation with glucuronic forms ester or acyl and ether or phenolic glucuronide, which are the three main metabolites.

Route of elimination

Excreted by kidneys as free salicylic acid (10%), salicyluric acid (75%), salicylic phenolic (10%) and acyl glucuronide (5%), and gentisic acid (less than 1%).

Half life

The plasma half-life for salicylate is 2 to 3 hr in low doses and about 12 hr at usual anti-inflammatory doses. The half-life of salicylate may be as long as 15 to 30 hr at high therapeutic doses or when there is intoxication.

Clearance
Not Available
Toxicity

Oral LD50 values (mg/kg) for mouse, rat and rabbit are 1110, 887 and 1300, respectively. Oral LD50 values for child and adult human (mg/kg) are 228 and 506, respectively. Although systemic toxicity from topical administration is rare, methyl salicylate can be absorbed in intract skin to cause stimulation of the central nervous system respiratory center, disturbance of lipid and carbohydrate metabolism, and disturbance of intracellular respiration. Severe toxicity can result in acute lung injury, lethargy, coma, seizures, cerebral edema, and death. In case of salicylate poisoning, the treatment consists of general supportive care, gastrointestinal decontamination with activated charcoal in cases of salicylate ingestion, and monitoring of serum salicylate concentrations. Bicarbonate infusions or hemodialysis can be used to achieve enhanced salicylate elimination [7].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Methyl salicylate.Approved
AcarboseMethyl salicylate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolMethyl salicylate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methyl salicylate.Approved, Vet Approved
AlbiglutideMethyl salicylate may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Aldosterone.Experimental, Investigational
AlogliptinMethyl salicylate may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Methyl salicylate.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Methyl salicylate is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Methyl salicylate.Approved
Ammonium chlorideThe serum concentration of Methyl salicylate can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Methyl salicylate.Approved
AncrodMethyl salicylate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Methyl salicylate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Anistreplase.Approved
Antithrombin III humanMethyl salicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMethyl salicylate may increase the anticoagulant activities of Apixaban.Approved
ArdeparinMethyl salicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Methyl salicylate.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methyl salicylate.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Methyl salicylate.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Batroxobin.Experimental
BecaplerminMethyl salicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Bemiparin.Approved, Investigational
BenazeprilMethyl salicylate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Methyl salicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Betamethasone.Approved, Vet Approved
BivalirudinMethyl salicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Brinzolamide.Approved
BromocriptineMethyl salicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Methyl salicylate.Experimental
BumetanideMethyl salicylate may decrease the diuretic activities of Bumetanide.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Methyl salicylate.Investigational
CanagliflozinMethyl salicylate may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilMethyl salicylate may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Methyl salicylate.Approved
CaptoprilMethyl salicylate may decrease the antihypertensive activities of Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Methyl salicylate.Experimental, Investigational
CertoparinMethyl salicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamideMethyl salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilMethyl salicylate may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Methyl salicylate.Approved
Citric AcidMethyl salicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Methyl salicylate.Approved, Nutraceutical
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Methyl salicylate.Experimental
ClorindioneMethyl salicylate may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Cortisone acetate.Approved
Dabigatran etexilateMethyl salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMethyl salicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMethyl salicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinMethyl salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanMethyl salicylate may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Methyl salicylate.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Deflazacort.Approved
DelaprilMethyl salicylate may decrease the antihypertensive activities of Delapril.Experimental
dersalazinedersalazine may increase the anticoagulant activities of Methyl salicylate.Investigational
DesirudinMethyl salicylate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dexketoprofen.Approved, Investigational
DextranMethyl salicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Methyl salicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Methyl salicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Methyl salicylate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diclofenamide.Approved
DicoumarolMethyl salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Methyl salicylate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Methyl salicylate.Approved
DiphenadioneMethyl salicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Methyl salicylate.Approved
DisopyramideMethyl salicylate may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideMethyl salicylate may increase the hypoglycemic activities of Dulaglutide.Approved
Edetic AcidMethyl salicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMethyl salicylate may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinMethyl salicylate may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilMethyl salicylate may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMethyl salicylate may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxaparinMethyl salicylate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Methyl salicylate.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Methyl salicylate.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Methyl salicylate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyl salicylate.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Methyl salicylate.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Estrone sulfate.Approved
Etacrynic acidMethyl salicylate may decrease the diuretic activities of Etacrynic acid.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateMethyl salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideMethyl salicylate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Ferulic acidMethyl salicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fibrinolysin.Investigational
fluasteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fludrocortisone.Approved
FluindioneMethyl salicylate may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Flurandrenolide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone propionate.Approved
FondaparinuxMethyl salicylate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMethyl salicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilMethyl salicylate may decrease the antihypertensive activities of Fosinopril.Approved
FurosemideMethyl salicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMethyl salicylate may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Methyl salicylate.Approved, Investigational, Nutraceutical
GliclazideMethyl salicylate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMethyl salicylate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMethyl salicylate may increase the hypoglycemic activities of Glipizide.Approved
GlyburideMethyl salicylate may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Methyl salicylate.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Methyl salicylate is combined with HE3286.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Methyl salicylate.Experimental
HeparinMethyl salicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methyl salicylate.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Methyl salicylate.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Methyl salicylate.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Methyl salicylate.Approved, Nutraceutical
IdraparinuxMethyl salicylate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Methyl salicylate.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Methyl salicylate.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Methyl salicylate.Approved, Investigational
ImidaprilMethyl salicylate may decrease the antihypertensive activities of Imidapril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Methyl salicylate.Investigational
Insulin AspartMethyl salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirMethyl salicylate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineMethyl salicylate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineMethyl salicylate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanMethyl salicylate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproMethyl salicylate may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Methyl salicylate.Investigational
LepirudinMethyl salicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMethyl salicylate may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Methyl salicylate.Experimental
LiraglutideMethyl salicylate may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilMethyl salicylate may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Methyl salicylate is combined with ME-609.Investigational
MecaserminMethyl salicylate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Medrysone.Approved
MelagatranMethyl salicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Methyl salicylate.Approved
MetforminMethyl salicylate may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Methyl salicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Methylprednisolone.Approved, Vet Approved
MifepristoneMethyl salicylate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolMethyl salicylate may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Methyl salicylate.Approved
MoexiprilMethyl salicylate may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone.Approved, Vet Approved
NadroparinMethyl salicylate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMethyl salicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Methyl salicylate.Investigational
NateglinideMethyl salicylate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Methyl salicylate is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Methyl salicylate.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Methyl salicylate.Approved
OmapatrilatMethyl salicylate may decrease the antihypertensive activities of Omapatrilat.Investigational
OtamixabanMethyl salicylate may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateMethyl salicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineMethyl salicylate may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateMethyl salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Methyl salicylate.Approved, Investigational
PerindoprilMethyl salicylate may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneMethyl salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMethyl salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Methyl salicylate.Experimental
PioglitazoneMethyl salicylate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideMethyl salicylate may decrease the diuretic activities of Piretanide.Experimental
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Methyl salicylate.Approved
PramlintideMethyl salicylate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Methyl salicylate.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Methyl salicylate.Approved
Protein CMethyl salicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanMethyl salicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMethyl salicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilMethyl salicylate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinineMethyl salicylate may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Methyl salicylate.Investigational
RamiprilMethyl salicylate may decrease the antihypertensive activities of Ramipril.Approved
RepaglinideMethyl salicylate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineMethyl salicylate may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methyl salicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Reteplase.Approved
ReviparinMethyl salicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Methyl salicylate.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Rimexolone.Approved
RivaroxabanMethyl salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Rosiglitazone.Approved, Investigational
Salicylic acidSalicylic acid may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Methyl salicylate.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Saruplase.Experimental
SaxagliptinMethyl salicylate may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methyl salicylate.Approved, Vet Approved
SitagliptinMethyl salicylate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SpiraprilMethyl salicylate may decrease the antihypertensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Methyl salicylate.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Streptokinase.Approved, Investigational
SulfadiazineMethyl salicylate may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleMethyl salicylate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleMethyl salicylate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulodexideMethyl salicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibMethyl salicylate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilMethyl salicylate may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Methyl salicylate.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Methyl salicylate.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ticlopidine.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tinzaparin.Approved
TioclomarolMethyl salicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Methyl salicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tixocortol.Approved
TolazamideMethyl salicylate may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideMethyl salicylate may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideMethyl salicylate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilMethyl salicylate may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Methyl salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Methyl salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Methyl salicylate.Approved, Investigational
Trolamine salicylateMethyl salicylate may increase the anticoagulant activities of Trolamine salicylate.Approved
TroxerutinMethyl salicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Methyl salicylate.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Methyl salicylate.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Methyl salicylate.Approved
WarfarinMethyl salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMethyl salicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilMethyl salicylate may decrease the antihypertensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. He YY, Yan Y, Zhang HF, Lin YH, Chen YC, Yan Y, Wu P, Fang JS, Yang SH, Du GH: Methyl salicylate 2-O-beta-d-lactoside alleviates the pathological progression of pristane-induced systemic lupus erythematosus-like disease in mice via suppression of inflammatory response and signal transduction. Drug Des Devel Ther. 2016 Sep 29;10:3183-3196. eCollection 2016. [PubMed:27729775]
  2. Xin W, Huang C, Zhang X, Xin S, Zhou Y, Ma X, Zhang D, Li Y, Zhou S, Zhang D, Zhang T, Du G: Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice. Br J Pharmacol. 2014 Jul;171(14):3526-38. doi: 10.1111/bph.12715. [PubMed:24712652]
  3. Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ: Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004 Apr 24;328(7446):995. Epub 2004 Mar 19. [PubMed:15033879]
  4. Higashi Y, Kiuchi T, Furuta K: Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther. 2010 Jan;32(1):34-43. doi: 10.1016/j.clinthera.2010.01.016. [PubMed:20171409]
  5. Derry S, Matthews PR, Wiffen PJ, Moore RA: Salicylate-containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2014 Nov 26;(11):CD007403. doi: 10.1002/14651858.CD007403.pub3. [PubMed:25425092]
  6. Moore RA, Derry S, McQuay HJ: Topical analgesics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2010;(7). pii: CD008609. [PubMed:25411557]
  7. Thompson TM, Toerne T, Erickson TB: Salicylate Toxicity from Genital Exposure to a Methylsalicylate-Containing Rubefacient. West J Emerg Med. 2016 Mar;17(2):181-3. doi: 10.5811/westjem.2016.1.29262. Epub 2016 Mar 2. [PubMed:26973745]
  8. FDA SALONPAS® Pain Relief Patch Clinical Review [Link]
  9. Norwegian Food Safety Authority: Methyl salicylate risk review [Link]
External Links
Human Metabolome Database
HMDB34172
KEGG Drug
D01087
KEGG Compound
C12305
PubChem Compound
4133
PubChem Substance
347827876
ChemSpider
13848808
ChEBI
31832
ChEMBL
CHEMBL108545
Drugs.com
Drugs.com Drug Page
Wikipedia
Methyl_salicylate
AHFS Codes
  • 28:08.04.24 — Salicylates
MSDS
Download (55.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentPain, Acute1
2, 3WithdrawnTreatmentHIV-infection/Aids / Immune Reconstitution Inflammatory Syndrome / Immune Reconstitution Syndrome / Tuberculosis1
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentAggressive Periodontitis1
4CompletedTreatmentSub-acute Back Pain1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
Not AvailableRecruitingTreatmentPeriodontitis / Type 2 Diabetes Mellitus1
Not AvailableUnknown StatusTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Aerosol, sprayCutaneous; Topical; Transdermal
RinseOral
SprayTopical23 g/100g
MouthwashBuccal
SolutionTopical
OilPercutaneous; Topical; Transdermal
PowderTopical
LotionTopical10 g/g
LotionTopical10 g/100mL
SprayTopical
GelTopical
SalveTopical
LiquidTopical
OilTopical
OintmentTopical
CreamTopical250 mg/mL
PatchCutaneous; Topical; Transdermal
PasteTopical
LiquidTopical980 mg/mL
SolutionTransdermal3 g/100mL
LiquidOral
StickTopical
OilTopical60 g/100mL
OintmentTopical13.5 g/100g
LiquidRespiratory (inhalation)
OintmentTopical10.5 g/100g
OilTopical105 mg/mL
PatchTopical
LotionTopical
MouthwashOral
LinimentTopical
JellyNasal
GelTopical105 mg/g
LotionTopical20 g/100g
EmulsionTopical
GelPercutaneous; Topical; Transdermal
PatchPercutaneous; Topical; Transdermal
Aerosol, sprayPercutaneous; Topical; Transdermal
Aerosol, foamPercutaneous; Topical; Transdermal
PlasterTransdermal
PlasterTopical
LiquidCutaneous; Topical; Transdermal
Kit
LiquidTopical10 g/100g
PatchTopical10 mg/100mg
PatchTopical10 g/100g
MouthwashDental
EmulsionTopical10 %
CreamTopical100 mg/g
PatchTransdermal
OintmentTopical10.5 g/90g
OintmentTopical15.75 g/150g
CreamTopical
OilTransdermal
LiquidTopical
PlasterTopical; Transdermal
PoulticeTransdermal160 mg/17g
PoulticeTransdermal105 mg/17.5g
LiquidTopical200 mg/g
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8809615No2010-01-032030-01-03Us
US9233184No2007-08-012027-08-01Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-8.6MSDS
boiling point (°C)220-224MSDS
water solubilitySlightly solubleMSDS
logP2.5MSDS
Predicted Properties
PropertyValueSource
Water Solubility5.73 mg/mLALOGPS
logP2.07ALOGPS
logP2.32ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)9.72ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity40.06 m3·mol-1ChemAxon
Polarizability14.98 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-4c121b87ee97a30f4150
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9800000000-aeff759175e190d33827
GC-MS Spectrum - EI-BGC-MSsplash10-00dl-9700000000-8449a003796d4c61d429
Mass Spectrum (Electron Ionization)MSsplash10-00dl-9800000000-1d56d6cf07db519b50e2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-eba52e49290e16ea60c0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uk9-0900000000-684f1c8a3cf324183257
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uk9-9300000000-a594ffaab84fc15a2edc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-76d5fc81bafad7c2222c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0900000000-dae7a80af6333acd66fc
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gb9-9600000000-09304803bc773495c704
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0fk9-3900000000-e2029bf3c75775175ff3
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-hydroxybenzoic acid esters. These are benzoic acid esters where the benzene ring is ortho-substituted with a hydroxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
o-Hydroxybenzoic acid esters
Alternative Parents
Salicylic acid and derivatives / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Methyl esters / Monocarboxylic acids and derivatives / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
O-hydroxybenzoic acid ester / Salicylic acid or derivatives / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Methyl ester / Carboxylic acid ester / Carboxylic acid derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
salicylates, benzoate ester (CHEBI:31832) / a small molecule (CPD-6442)

Drug created on November 30, 2015 12:10 / Updated on November 19, 2017 20:34